Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers

Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (>= 38.0 degrees C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.

Automated summary

Hospital-based surveillance found that healthcare workers who received the adenovirus-vectored COVID-19 vaccine experienced higher rates of systemic adverse events compared to mRNA vaccine recipients. Common adverse events among adenovirus-vectored vaccine recipients included fatigue, myalgia, headache, and fever, with most symptoms resolving within 2 days. Both COVID-19 vaccines were generally safe with few serious adverse events reported.